Marinomed Biotech AG (the "Company") announces that the Company was informed by the two shareholders aws Mittelstandsfonds Beteiligungs GmbH & Co. KG ("aws Mittelstandsfonds") and Invest Unternehmensbeteiligungs AG ("Invest AG") on 16 October 2019 that aws Mittelstandsfonds and Invest AG have sold in total 115,000 Marinomed shares from their holdings through an accelerated bookbuilding transaction to institutional investors (the "Transaction").
The following information, put in quotation marks, is taken from the notfication of the Company by aws Mittelstandsfonds and Invest AG:
"NOT FOR DISTRIBUTION OR PUBLICATION, EITHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, CANADA, JAPAN OR AUSTRALIA.
aws Mittelstandsfonds Beteiligungs GmbH & Co. KG ("aws Mittelstandsfonds") and Invest Unternehmensbeteiligungs AG ("Invest AG") hereby announce that today, 16 October 2019, each of aws Mittelstandsfonds and Invest AG have sold 47,500 shares in Marionomed Biotech AG (ISIN ATMARINOMED6, "Marinomed shares"), thus in aggregate 95,000 Marinomed shares, from their holdings to institutional investors by means of an accelerated bookbuilding transaction (the "ABB"). This amounts to 6.5% of Marinomed Biotech AG's share capital. The upsize alternative of up to 45,000 additional Marinomed shares was exercised in an amount of 20,000 additional Marionomed shares.
The Marinomed shares were sold for EUR 95.00 each. The total sale proceeds of the ABB for aws Mittelstandsfonds and Invest AG therefore amounts to EUR 10.93 million. Settlement of Marinomed shares placed in the ABB is scheduled for 18 October 2019.
Erste Group Bank AG acted as the sole bookrunner.
Following completion of the ABB, aws Mittelstandsfonds and Invest AG each still hold approximately 3.2% of the share capital of Marinomed Biotech AG. For these shares the lock-up commitment of aws Mittelstandsfonds and Invest AG, which was entered into as part of the IPO, continues to apply.
This announcement constitutes neither an offer to buy securities nor a solicitation of an offer to buy securities in the United States of America, Germany, Austria or other countries. The securities are not sold or offered to be sold in the United States of America under the rules of the US Securities Act of 1933, as amended. A public offer of the securities is neither made in Austria nor in any other jurisdiction. Any offer of shares under the ABB shall be made solely on the basis of an exemption from the obligation to publish a prospectus in accordance with Article 1 (4) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and is exclusivelyintended for qualified investors within the meaning of Article 2 (e) of the Prospectus Regulation. Offers to purchase the securities by persons other than qualified investors within the meaning of Article 2 (e) of the Prospectus Regulation will be rejected without exception."
About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna and has been listed in the Prime Market of the Vienna Stock Exchange since February 1, 2019. The company focuses on the development of innovative products based on patent-protected technology platforms in the field of respiratory and ophthalmological diseases. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Further information is available at: www.marinomed.com.